Law360, New York ( March 20, 2012, 7:46 PM EDT) -- On March 20, 2012, the U.S. Supreme Court unanimously reversed the Court of Appeals for the Federal Circuit holding that Prometheus's patents — claiming methods for determining the optimal dosages of thiopurine drugs to treat certain diseases — were directed to nonstatutory subject matter pursuant to 35 U.S.C. § 101 and therefore not patent-eligible. Mayo Collaborative Servs. v. Prometheus Labs. Inc., 566 U.S. ___ (2012)....
Law360 is on it, so you are, too.
A Law360 subscription puts you at the center of fast-moving legal issues, trends and developments so you can act with speed and confidence. Over 200 articles are published daily across more than 60 topics, industries, practice areas and jurisdictions.
A Law360 subscription includes features such as
- Daily newsletters
- Expert analysis
- Mobile app
- Advanced search
- Judge information
- Real-time alerts
- 450K+ searchable archived articles
And more!
Experience Law360 today with a free 7-day trial.